Industry hails Supreme Court's decision to maintain mifepristone abortion pill's access

In the wake of the Supreme Court’s decision to preserve mail-order access to the abortion pill mifepristone, leaders from across the industry are weighing in with their support.

Members of the trade groups the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) plus the American Medical Association (AMA) and CEOs from women's health drugmakers lauded Thursday's ruling.